-
Je něco špatně v tomto záznamu ?
Lessons from 30 years of clinical diagnosis and treatment of congenital adrenal hyperplasia in five middle European countries
J Kovacs, F Votava, G Heinze, J Solyom, J Lebl, Z Pribilincova, H Frisch, T Battelino, F Waldhauser, European Workshop on Paediatric Endocrinology-Congenital Adrenal Hyperplasia Study Group Middle
Jazyk angličtina Země Spojené státy americké
Typ dokumentu práce podpořená grantem
Grantová podpora
NE6133
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
NLK
Free Medical Journals
od 1997 do Před 1 rokem
PubMed
11443151
DOI
10.1210/jcem.86.7.7638
Knihovny.cz E-zdroje
- MeSH
- časové faktory MeSH
- kongenitální adrenální hyperplazie * diagnóza epidemiologie genetika terapie MeSH
- lidé MeSH
- míra přežití MeSH
- pohlavní dimorfismus MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
- Maďarsko MeSH
- Rakousko MeSH
- Slovenská republika MeSH
- Slovinsko MeSH
Despite the fact that congenital adrenal hyperplasia (CAH) is one of the most common inborn endocrine disorders, some patients are not identified, or may even die, in an acute salt-losing crisis. In a retrospective study covering the last 30 yr, we examined the time elapsing before diagnosis of CAH patients, in 5 Middle European countries, and the mortality rate in diagnosed patients and their siblings during childhood; we also attempted to estimate how many patients are not diagnosed clinically each year. Basic and follow-up clinical data and the family histories of 484 patients with classical forms of CAH diagnosed between 1969 and 1998 were collected and recorded in 5 Middle European countries. The sex-ratio, time elapsing before diagnosis, and mortality among siblings and patients were calculated, and the number of undiagnosed patients was estimated. We found significantly fewer genetic males (43.0%) than females (57.0%) among 484 classic CAH patients, and the percentage of diagnosed boys did not increase with time; 64.7% of them suffered from the salt-wasting (SW) form, and 35.3% from the simple virilizing (SV) form, of the disease. The diagnosis of CAH was established significantly later in males than in females in both forms [SW: 26 vs. 13 days (median), P < 0.0001; SV: 5.0 vs. 2.8 yr, P = 0.03]. Infant mortality in the general population was significantly lower than in either siblings (1.8% vs. 7.0%; P < 0.0001) or in SW (2.29% vs. 11.3%; P < 0.0001). According to our calculations, by our current praxis of clinical ascertainment, 2-2.5 SW and up to 5 SV stay undiagnosed, out of 40 expected CAH patients per year in the countries investigated. Both clinical detection and treatment of CAH patients, at least in males, were insufficient in the five Middle European countries examined during the last 30 yr. Neonatal mass screening and/or greater awareness of the medical community are discussed as ways of improving the efficacy of CAH management. Our experience may be applicable to other countries with similar health care systems.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13025854
- 003
- CZ-PrNML
- 005
- 20130902161522.0
- 007
- ta
- 008
- 130726s2001 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1210/jcem.86.7.7638 $2 doi
- 035 __
- $a (PubMed)11443151
- 040 __
- $a ABA008 $d ABA008 $e AACR2 $b cze
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kovacs J $u Department of Pediatrics, University of Vienna, A-1090 Vienna, Austria.
- 245 10
- $a Lessons from 30 years of clinical diagnosis and treatment of congenital adrenal hyperplasia in five middle European countries / $c J Kovacs, F Votava, G Heinze, J Solyom, J Lebl, Z Pribilincova, H Frisch, T Battelino, F Waldhauser, European Workshop on Paediatric Endocrinology-Congenital Adrenal Hyperplasia Study Group Middle
- 504 __
- $a Literatura
- 520 9_
- $a Despite the fact that congenital adrenal hyperplasia (CAH) is one of the most common inborn endocrine disorders, some patients are not identified, or may even die, in an acute salt-losing crisis. In a retrospective study covering the last 30 yr, we examined the time elapsing before diagnosis of CAH patients, in 5 Middle European countries, and the mortality rate in diagnosed patients and their siblings during childhood; we also attempted to estimate how many patients are not diagnosed clinically each year. Basic and follow-up clinical data and the family histories of 484 patients with classical forms of CAH diagnosed between 1969 and 1998 were collected and recorded in 5 Middle European countries. The sex-ratio, time elapsing before diagnosis, and mortality among siblings and patients were calculated, and the number of undiagnosed patients was estimated. We found significantly fewer genetic males (43.0%) than females (57.0%) among 484 classic CAH patients, and the percentage of diagnosed boys did not increase with time; 64.7% of them suffered from the salt-wasting (SW) form, and 35.3% from the simple virilizing (SV) form, of the disease. The diagnosis of CAH was established significantly later in males than in females in both forms [SW: 26 vs. 13 days (median), P < 0.0001; SV: 5.0 vs. 2.8 yr, P = 0.03]. Infant mortality in the general population was significantly lower than in either siblings (1.8% vs. 7.0%; P < 0.0001) or in SW (2.29% vs. 11.3%; P < 0.0001). According to our calculations, by our current praxis of clinical ascertainment, 2-2.5 SW and up to 5 SV stay undiagnosed, out of 40 expected CAH patients per year in the countries investigated. Both clinical detection and treatment of CAH patients, at least in males, were insufficient in the five Middle European countries examined during the last 30 yr. Neonatal mass screening and/or greater awareness of the medical community are discussed as ways of improving the efficacy of CAH management. Our experience may be applicable to other countries with similar health care systems.
- 590 __
- $a bohemika - dle Pubmed
- 650 12
- $a kongenitální adrenální hyperplazie $x diagnóza $x epidemiologie $x genetika $x terapie $7 D000312
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a lidé $7 D006801
- 650 02
- $a mužské pohlaví $7 D008297
- 650 02
- $a retrospektivní studie $7 D012189
- 650 02
- $a pohlavní dimorfismus $7 D012727
- 650 02
- $a míra přežití $7 D015996
- 650 02
- $a časové faktory $7 D013997
- 651 _2
- $a Rakousko $x epidemiologie $7 D001317
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 651 _2
- $a Maďarsko $x epidemiologie $7 D006814
- 651 _2
- $a Slovenská republika $x epidemiologie $7 D018154
- 651 _2
- $a Slovinsko $x epidemiologie $7 D017524
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Votava, Felix, $d 1957- $7 xx0060357
- 700 1_
- $a Heinze G
- 700 1_
- $a Solyom J
- 700 1_
- $a Lebl, Jan, $d 1955- $7 jn19990010093
- 700 1_
- $a Pribilincová, Zuzana $7 xx0073901
- 700 1_
- $a Frisch H
- 700 1_
- $a Battelino T
- 700 1_
- $a Waldhauser F
- 700 1_
- $a Middle European Workshop on Paediatric Endocrinology-Congenital Adrenal Hyperplasia Study Group
- 773 0_
- $t Journal of Clinical Endocrinology & Metabolism $x 0021-972X $g Roč. 86, č. 7 (2001), s. 2958-2964 $p J Clin Endocrinol Metab $w MED00002582
- 773 0_
- $p J Clin Endocrinol Metab $g 86(7):2958-64, 2001 Jul $x 0021-972X
- 910 __
- $a ABA008 $y 3 $z 0
- 990 __
- $a 20130726122432 $b ABA008
- 991 __
- $a 20130902162009 $b ABA008
- 999 __
- $a ok $b bmc $g 989649 $s 824258
- BAS __
- $a 3
- BMC __
- $a 2001 $b 86 $c 7 $d 2958-2964 $i 0021-972X $m The Journal of clinical endocrinology and metabolism $x MED00002582
- GRA __
- $a NE6133 $p MZ0
- LZP __
- $c NLK115 $d 20130902 $a 2013-07/ew